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Photodynamic therapy (PDT) for cutaneous malignancies has been found to be an effective 
treatment with a range of photosensitizers. The phthalocyanine Pc 4 was developed initially for 
PDT of primary or metastatic cancers in the skin. A Phase I trial was initiated to evaluate the 
safety and pharmacokinetic profiles of systemically administered Pc 4 followed by red light (Pc 
4-PDT) in cutaneous malignancies. A dose-escalation study of Pc 4 (starting dose 0.135 mg/
m2) at a fixed light fluence (135 J/cm2 of 675-nm light) was initiated in patients with primary or 
metastatic cutaneous malignancies with the aim of establishing the maximum tolerated dose 
(MTD). Blood samples were taken at intervals over the first 60 h post-PDT for pharmacokinetic 
analysis, and patients were evaluated for toxicity and tumor response. A total of three patients 
(two females with breast cancer and one male with cutaneous T-cell lymphoma) were enrolled 
and treated over the dose range of 0.135 mg/m2 (first dose level) to 0.54 mg/m2 (third dose level). 
Grade 3 erythema within the photoirradiated area was induced in patient 2, and transient tumor 
regression in patient 3, in spite of the low photosensitizer doses. Pharmacokinetic observations 
fit a three-compartment exponential elimination model with an initial rapid distribution phase 
(∼0.2 h) and relatively long terminal elimination phase (∼28 h), Because of restrictive exclusion 
criteria and resultant poor accrual, the trial was closed before MTD could be reached. While the 
limited accrual to this initial Phase I study did not establish the MTD nor establish a complete 
pharmacokinetic and safety profile of intravenous Pc 4-PDT, these preliminary data support 
further Phase I testing of this new photosensitizer.
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other countries worldwide, and further clinical studies are in pro-
cess with these and other photosensitizers (Dolmans et al., 2003; 
Brown et al., 2004; Huang et al., 2008).
For metastatic breast cancer to the chest wall, PDT has been 
reported to produce partial or complete responses in a significant pro-
portion of patients using several different photosensitizers, including 
rostaporfin (Purlytin®; Mang et al., 1998), Photofrin® (Allison et al., 
2001; Cuenca et al., 2004), motexafin lutetium (Antrin®; Renschler 
et al., 1998; Dimofte et al., 2002), and temoporfin (Foscan®; Wyss 
et al., 2001). Trials through 2004 have been reviewed (Allison et al., 
IntroductIon
Photodynamic therapy (PDT) is now approved by the US Food 
and Drug Administration (FDA) for a range of cancers and non-
cancerous indications: specifically, early and advanced lung cancer, 
advanced esophageal cancer, and Barrett’s esophagus with porfimer 
sodium (Photofrin®) as the photosensitizer; age-related macular 
degeneration with benzoporphyrin derivative (Verteporfin®); and 
actinic keratosis with 5-aminolevulinic acid (ALA; Levulan®) or 
methyl aminolevulinate (Metvixia®). Approvals for other indica-
tions and additional photosensitizers have been received in many Frontiers in Oncology | Radiation Oncology    June 2011  | Volume 1  |  Article 14  |  2
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administered with increasing fluence. A dose-escalation study of 
Pc 4 with a fixed light dose (135 J/cm2 of 675 ± 5 nm light from 
a laser) was designed. Since the starting dose of Pc 4 (0.135 mg/
m2; 0.0039 mg/kg), as set in negotiations with the FDA, was lower 
than those of any of the currently used photosensitizers, a 100% 
dose-escalation scheme in single-patient cohorts was approved with 
the endpoint being skin erythema in the treated (illuminated) area, 
after which three-patient cohorts were required.
The pharmacokinetic sampling strategy was based on elimina-
tion half-life and clearance values for Pc 4 determined in mice 
(Egorin et al., 1999). A distribution half-life of 10 min and an 
elimination half-life of 36 h were modeled. During the 2-h Pc 4 
infusion, blood samples were taken at 0, 30, 60, and 120 min and 
then post-infusion samples were taken at 0.5, 1, 2, 4, 8, 12, 18, 24, 
36, 48, and 60 h.
PatIent cohort and exclusIon crIterIa
The protocol was approved by the Institutional Review Board of 
University Hospitals of Cleveland, and written informed consent 
was obtained from each volunteer. Patients with pathologically 
confirmed cutaneous or superficial nodular metastatic/locally 
recurrent breast adenocarcinoma or head-and-neck squamous 
cell carcinoma with a minimum of 1 well-defined tumor lesion 
of 1.5–3.0 cm2 were eligible. Up to two separate lesions could be 
treated with the maximum of 16 cm2 area per treatment site to allow 
a 3-cm × 3-cm tumor mass with a 1-cm margin to be illuminated. 
These solid tumor patients were judged to have no potential for cure 
by conventional treatment modalities including surgery, radiation, 
and chemotherapy. Prior treatment with radiation and chemo-
therapy was allowed if patients were without these conventional 
treatments for at least 4 weeks prior to study entry. Additionally, 
patients with biopsy-confirmed, conventional treatment-refractory 
cutaneous T-cell lymphoma (CTCL) or Kaposi’s sarcoma with simi-
lar skin lesion criteria were also eligible. Exclusion criteria included: 
hematologic dysfunction (absolute neutrophil count, <1500/μL; 
hemoglobin, <9 g/dL; platelets, <100,000/μL); coagulation dys-
function (APTT and PT > 1.2× normal); hepatic dysfunction 
(B12 > 1.5 mg/dL; transaminases > 2× normal); renal dysfunction 
(creatinine > 2.0 mg/dL or creatinine clearance < 50 mL/min); 
and lipid disorder (cholesterol and triglyceride serum levels > 3× 
normal) within 7 days of protocol entry. Other exclusion criteria 
included: cardiovascular dysfunction (MI within 6 months; active 
congestive heart failure); known photosensitivity diseases includ-
ing porphyria and xeroderma pigmentosum; and the concomitant 
use of potentially photosensitizing medications including certain 
antibiotics (tetracyclines, sulfas), diuretics (hydrochlorothiazide, 
furosemide), and phenothiazines.
FormulatIon and InFusIon oF Pc 4
Pc 4 drug was received in the University Hospitals Investigational 
Pharmacy as dual vials, one with 1 mg Pc 4 and 5 mg Povidone, the 
second with 1 mL of Cremophor EL:ethanol::1:1 (NCI Diluent 12). 
Under contract with the NCI, the vials were prepared by BenVenue 
Laboratories, Oakwood, OH, USA. The hospital pharmacist dis-
solved the drug powder in NCI Diluent 12, then diluted it with 9 
volumes of normal saline. Patients were given the formulated Pc 4 
intravenously through an infusion pump over a 2-h period.
2004). For cancer, precancerous lesions, and benign conditions of 
the skin, the most widely used procedure involves topical delivery of 
ALA formulated as Levulan® or Metvixia® and photoirradiation after 
a delay to allow metabolic conversion of ALA to the photosensitizer, 
protoporphyrin IX (Morton et al., 2008). Nonetheless, PDT with 
preformed photosensitizers, such as Photofrin®, has been found to 
be efficacious against skin cancers (e.g., Oseroff et al., 2006). In spite 
of the demonstrated success of PDT, there are no US FDA approvals 
for the use of PDT in skin cancers.
Pc 4 is a silicon phthalocyanine first synthesized in the labora-
tory of M.E. Kenney, Chemistry Department, Case Western Reserve 
University (CWRU; Figure 1; Oleinick et al., 1993). After dem-
onstration of the efficacy of Pc 4 as a photosensitizer for PDT 
against a variety of cancer cell lines in vitro and model tumors 
in vivo (e.g., Zaidi et al., 1993; Agarwal et al., 1996; Anderson et al., 
1997, 1998), investigators at CWRU petitioned the Drug Decision 
Network (DDN), a division of the Cancer Therapy Evaluation 
Program (CTEP) of the National Cancer Institute (NCI), for help 
in conducting the additional studies needed for application to the 
FDA for an investigational new drug (IND) designation with per-
mission to conduct the first clinical trial of PDT with systemic 
delivery of Pc 4 for cutaneous malignancies. From 1995 to 1998, 
CTEP oversaw the good manufacturing practices (GMP) synthesis 
of Pc 4, reformulation into an acceptable vehicle, pharmacokinetic 
studies in mice (Egorin et al., 1999), further efficacy studies (Colussi 
et al., 1999), and toxicity studies conducted under good laboratory 
practices (GLP). The resultant data were submitted to the FDA in 
the form of a drug master file (DMF) that was cross-referenced 
by CWRU investigators in their application for an IND (#61,155).
A Phase I trial of PDT with intravenously administered Pc 4 for 
cutaneous malignancies was initially activated and further amended 
in an attempt to improve patient accrual. In spite of all efforts, 
accrual was poor and the trial was closed. However, three patients 
were treated with interesting results. This paper reports on these 
limited clinical and pharmacologic results as well as commentary 
on further clinical development of Pc 4-PDT.
materIals and methods
trIal desIgn
The Phase I protocol was designed first to escalate the dose of Pc 
4 at a constant light fluence to determine the maximum tolerated 
dose (MTD), after which a Pc 4 dose one level lower would be 
Figure 1 | Structures of Pc 4 and Pc 34. Pc 4 is the photosensitizer studied 
in the clinical trial. Pc 34 is a closely related molecule used as an internal 
standard for HPLC analysis.www.frontiersin.org  June 2011  | Volume 1  |  Article 14  |  3
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  termination, and subsequently at 0.5–60 h after infusion termina-
tion. Pc 4 was determined by high performance liquid chromatog-
raphy/tandem mass spectrometry according to a method developed 
by the Case Comprehensive Cancer Center Cancer Pharmacology 
Core Laboratory. Pc 4 and the closely analogous Pc 34 (Figure 1) 
internal standard were extracted from 200-μl aliquots of plasma 
with good efficiency. The organic extracts were evaporated to dry-
ness, reconstituted in chromatographic mobile phase, and injected 
into the liquid chromatograph. The chromatographic separation 
was accomplished on a reverse-phase column with an isocratic 
mobile phase consisting of methanol and ammonium formate 
buffer. Pc 4 and Pc 34 were detected by monitoring collision-
induced transitions of 718–557 m/z and 746–557 m/z, respectively. 
Plasma samples and concurrent quality control specimens were pre-
pared and analyzed in duplicate, and Pc 4 concentrations were cal-
culated in relation to calibration curves established over the range 
of 0.078–100 nM Pc 4 in plasma during each episode of sample 
analysis. The lower limit of quantitation corresponds with about 
2 × 10−15 mol of Pc 4 injected into the chromatographic column.
results
After activation of the trial, over the next 13 months, a large number 
of patients were identified by referring physicians and, of those, 
35 patients were screened to determine if they qualified for the 
trial. In spite of the intensive screening, no patients were found 
to fit all of the criteria for the trial. Recognizing that the inclu-
sion and exclusion criteria were written quite narrowly to satisfy 
requirements negotiated with the FDA, the investigators petitioned 
the FDA for expansion of the inclusion criteria to increase lesion 
size for treatment from 3 to 5 cm2, to allow concurrent hormonal 
therapy for breast cancer patients, and to include other tumors, 
such as colon cancer, that also metastasize to skin. The amended 
protocol was approved.
A total of three patients (two females with breast cancer and 
one male with CTCL) were enrolled and treated over the dose 
range of 0.135 mg/m2 (first dose level) to 0.54 mg/m2 (third dose 
level; Table 1). No dose-limiting systemic toxicities were encoun-
tered. The first two patients showed progressive disease at week 4 
following the first PDT treatment. However, quite unexpectedly 
early in the dose-escalation experience, patient 2 developed grade 
3 erythema at dose level 2 (0.27 mg/m2) for which expansion of 
patients treated at this dose level was required. Patient 3 went on 
to be treated at dose level 2 and tolerated therapy for 2 cycles. Since 
PhotodynamIc theraPy
Selected tumor sites were photoirradiated 24 h after administra-
tion of Pc 4. This time interval between drug delivery and light 
delivery was selected to allow differential tumor to normal skin 
drug clearance, based on preclinical animal studies (Egorin et al., 
1999). Each site received 135 J/cm2 at an irradiance of 100 mW/cm2 
with a 675-nm diode laser (LaserCare PDT 674-8, AOC Medical 
Systems, South Plainfield, NJ, USA). The surface of the skin tumor 
was illuminated through a fiberoptic cable terminating in a micro-
lens (Pioneer Optics Co., Windsor Locks, CT, USA). The laser unit 
was self-calibrated using the integrating sphere power meter of the 
diode laser. The microlens output was measured prior to and after 
each PDT session using a second remote power meter (LaserMate-
A/D-10 Head Calibration, Coherent, Inc., Santa Clara, CA, USA). 
The Laser Mate, in turn, was calibrated annually using a National 
Institute of Science and Technology (NIST)-traceable calibrator.
resPonse crIterIa
Tumor responses were determined using bidimensional measure-
ments to estimate the surface area of each lesion and measurement of 
the maximum lesion height. Photographs of the skin lesions also were 
taken immediately prior to PDT and every 4 weeks thereafter. Using a 
modification of standard NCI response criteria, a complete response 
was defined by a 100% decrease in lesion area and height at ≥4 weeks 
following PDT; a partial response as 50% decrease in area and/or 
height; stable disease as a <25% increase or <50% decrease in lesion 
area and <100% flattening of a raised lesion on height assessment; 
and progressive disease as >25% increase in lesion area and/or height.
Toxicity assessment included use of NCI Expanded Common 
Toxicity Criteria (version 2.0) for systemic toxicity as well as a modi-
fied five-grade peri-lesional skin (immediately outside the light 
field) toxicity assessment (Carraro and Pathak, 1988). Additionally, 
minimal erythema dose (MED) was assessed on distant skin in the 
first patient (study patient 3) after the one (study patient 2) who 
developed erythema following laser irradiation at the tumor site. 
A five-grade MED scoring system was used based on testing with a 
solar simulator using full spectrum UVA and UVB (280–400 nm) 
at a dose range of approximately 5–60 mJ/cm2.
PharmacokInetIcs oF Pc 4
Plasma samples were obtained from patient volunteers by veni-
puncture contralateral to the infusion site before infusion initia-
tion, at 0.5 and 1.0 h after infusion initiation, just before infusion 
Table 1 | Clinical tumor response and normal skin phototoxicity data.
Pt no. Tumor type Pc 4 dose 
(mg/m2)
No. PDT 
cycles
Tumor response Normal skin phototoxicity
1 Recurrent breast cancer 0.135 1 No erythema to adjacent skin following PDT; 
tumor progression at week 4
Not tested for MED; none observed 
clinically
2 Recurrent breast cancer 0.27 1 Grade 3 erythema to adjacent skin following 
PDT; tumor progression at week 4
Not tested for MED; none observed 
clinically
3 Refractory CTCL 0.27 2 Stable disease (<50%) response at weeks 4 
and 8
No change in MED pre- vs. post-Pc 
4; none observed clinically
0.54 2 Stable disease (<50%) response at week 12 
and 16; tumor progression at week 20
None observed clinicallyFrontiers in Oncology | Radiation Oncology    June 2011  | Volume 1  |  Article 14  |  4
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phase with an apparent half-life of 0.8 h, and a comparatively 
slow terminal elimination phase with a half-life of 28.6 h in 
this data set.
Patient 2 received a dose of 0.27 mg/m2 of Pc 4 in a 2-h infusion 
(Figure 2). The maximum plasma concentration (Cmax) of 22.3 nM 
measured in this experiment exceeded the Cmax of 2.9 nM measured 
in plasma from Patient 1 by more than sevenfold. Trapezoidal AUC 
calculated for the end of infusion and post-infusion data subset 
exceeded that observed in patient 1 by a similar multiple, and other 
calculated pharmacokinetic parameters also differed from those 
observed in Patient 1 (Figure 2; Tables 2 and 3). We decided con-
sequently to study another patient at a dose of 0.27 mg/m2 of Pc 
4. Results obtained from Patient 3 generally were similar to those 
obtained from Patient 2. Subsequently, Patient 3 was treated again 
with a dose of 0.54 mg/m2 of Pc 4. Data sets from all four experi-
ments appear in Figure 2.
Maximum measured Pc 4 concentrations did not coincide with 
the end of infusion sample time point in three of four experimental 
data sets (Table 3; Figure 2). The experimental protocol required 
infusion of small volumes of Pc 4 infusate solution at flow rates 
near the lower limit of capability of the infusion pumps used for 
drug delivery. We think that this variation in time of maximum 
measured Pc 4 concentration probably results from drug delivery 
inconsistency during the infusion phase of the experiment.
dIscussIon
While our Phase I study clearly did not establish the MTD nor a 
complete pharmacokinetic and safety profile of Pc 4, these pre-
liminary results support further Phase I testing of Pc 4-PDT. This 
is substantiated by the induction of grade 3 erythema within the 
treatment area in the second patient and transient (12 weeks) tumor 
regression, though not of sufficient duration to meet objective 
partial response (>50%) criteria, in the third patient treated in 
there was evidence of tumor regression (however, not sufficient 
to meet criteria for partial response), he was allowed to undergo 
an intra-patient dose-escalation to the third dose level. He was 
treated for two additional cycles at 0.54 mg/m2. By the time regula-
tory approval was secured to proceed with a second intra-patient 
dose-escalation, the patient developed progressive disease. In all, 
patient 3 received 4 cycles of therapy. MED testing on distant skin 
was conducted on patient 3 during the first treatment cycle and 
revealed no increase in cutaneous photosensitivity 1 day after infu-
sion of Pc 4 (pre-infusion MED: 41.83 mJ/cm2; 1 day post-infusion 
MED: 49.49 mJ/cm2).
As per protocol design, pharmacokinetics of Pc 4 were deter-
mined during drug infusion and for up to 60 h following the 
2-h infusion. Pc 4 concentrations were measurable in plasma 
specimens from patient 1 (0.135 mg/m2 Pc 4 over 2 h) obtained 
throughout the full duration of the sampling period (Figure 2). 
The plasma concentration of Pc 4 determined 60 h after infusion 
termination was about two times the lower limit of quantita-
tion of the assay method. The plasma concentration vs. time 
data subsets from the end of the infusion period through 60 h 
post-infusion were fit well by a three-exponential-term pharma-
cokinetic model. These terms characterize a rapid distribution 
phase with a half-life of 0.2 h, an intergrade elimination rate 
Figure 2 | Plasma Pc 4 concentration vs. time plots for four data sets 
obtained from three study volunteers in four treatment experiments. The 
inset presents data for the early period on an expanded time scale.
Table 2 | Maximum measured concentrations of Pc 4 (Cmax) and 
concentrations at end of infusion (Ceoi).
  Dose (mg/m2) Time  Cmax (h)  Cmax (nM)  Ceoi (nM)
Pt001 0.135  −1  2.9 1.7
Pt002 0.27  0  22.3  22.3
Pt003 0.27  −1  15.0 12.6
Pt003 0.54  −1.5  27 .4 10.6
The end of infusion time is defined as hour zero.
Table 3 | Pharmacokinetic parameters of Pc 4 in the elimination phase data subsets.
  Dose (mg/m2) B1  t1/2 (h)  B2 t1/2 (h)  B3 t1/2 (h)  AuC (last t; nM*h)  AuC (inf; nM*h)
Pt001 0.135  0.20  0.79  28.6  9.1  11.6
Pt002 0.27  0.13  2.43  64.6  80.8  148.9
Pt003 0.27  0.16  3.09  145.4  79.5  279.0
Pt003 0.54  0.18  2.04  90.9  91.5  231.4
A three-exponential term pharmacokinetics model described the data well. The B1, B2, and B3 half lives are tabulated for discernible rapid, intermediate rate, and 
comparatively slow elimination processes. Areas under curves calculated by trapezoidal integration through the time of last measurement are tabulated as AUC (last 
t). Areas under curves calculated from model time constant parameters and projected to infinite time are tabulated as AUC (inf).www.frontiersin.org  June 2011  | Volume 1  |  Article 14  |  5
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more sensitive to Pc 4-PDT in vitro than normal quiescent T-cells 
(Ohtola et al., 2010). Thus, these studies suggested that Pc 4-PDT 
has the potential to induce selective apoptosis of pathologic T-cells 
critical for T-cell-mediated diseases such as CTCL.
Based on the response of the CTCL lesions of patient 3 to low 
doses of Pc 4-PDT as described above and the evidence of high 
sensitivity of T-cells to this treatment, a new protocol was developed 
to apply Pc 4 topically to cutaneous malignancies and then photoir-
radiate 1 h later. This protocol was approved by the FDA under the 
existing IND number. A total of 43 patients were accrued to that 
trial, and the results have recently been published (Baron et al., 
2010). Briefly, it was shown that Pc 4-PDT with topically admin-
istered photosensitizer was well tolerated with no significant local 
toxicity or increased photosensitivity at distant sites. Furthermore, 
Pc 4-PDT was shown to have promising biologic effects, particularly 
in mycosis fungoides-type CTCL, in which 14 of 35 subjects dem-
onstrated a clinical response. A few patients in this trial provided 
biopsies of treated and untreated lesions; study of them produced 
evidence of increased apoptosis in tissue from responding lesions.
Our general conclusion is that, in spite of the early termination 
of the trial of systemically administered Pc 4 for PDT of cutaneous 
malignancies, Pc 4 has the potential to be an efficacious photo-
sensitizer in PDT protocols. Based on these limited clinical and 
pharmacokinetic data of intravenous Pc 4-PDT, further Phase I 
testing is being considered for other appropriate tumors including 
superficial, minimally invasive cancers of the bladder, esophagus, 
and head-and-neck, where Pc 4-PDT may have a better therapeutic 
index compared to surgery, radiation therapy, chemotherapy, or 
other photosensitizers.
acknowledgments
This research was supported by the Case Comprehensive Cancer 
Center Support Grant P30 CA43703, Program Project Grant P01 
CA48735, Phase I Contract U01 CA62502, and Skin Diseases 
Research Center Grant P50 AR055508 from the National Institutes 
of Health. Supported in part, by the DBJ Foundation.
this study. Further, these positive responses were obtained with a 
relatively low dose of photosensitizer (0.27 mg/m2). The highest 
dose tested was only 0.54 mg/m2, which is equivalent to 0.0156 mg/
kg. This dose level is nearly an order of magnitude lower than the 
recommended doses of Foscan® (0.1–0.15 mg/kg; Triesscheijn et al., 
2006), which are the lowest of all clinically approved photosensi-
tizers. The transient tumor regression observed at a very low dose 
for Pc 4, along with the absence of significant toxicity, is consistent 
with the potential of Pc 4 as a photosensitizer in PDT protocols for 
cutaneous malignancies.
Our pharmacokinetic observations fit a three-compartment 
exponential elimination model with an initial rapid distribution 
phase (∼0.2 h) and relatively long terminal elimination phase 
(∼28 h), which were consistent with preclinical observations in 
mice (Egorin et al., 1999).
Due to the restrictive eligibility criteria, and the resultant poor 
accrual that led to early closing of the trial, it was decided to explore 
the possibility of delivering Pc 4 topically to skin lesions. A topical 
formulation was developed in 30% propylene glycol/70% ethanol. 
Experiments to evaluate the ability of that formulation to deliver 
Pc 4 across the skin barrier were first conducted on human skin 
keratomes in vitro and resulted in a demonstration of the ability 
of Pc 4 to cross the stratum corneum and penetrate through the 
epidermis to the dermal–epidermal junction (Lam et al., 2011). 
Additional in vitro studies revealed a high susceptibility of T-cells 
to Pc 4-PDT: Jurkat T-cells were found to be much more sensitive 
to Pc 4-PDT than were A 431 human keratinocyte-derived cells, and 
the dominant mechanism of cell death in the T-cells was apoptosis 
(Ke et al., 2008). Apoptosis is a prominent mode of cell death for 
many cancer cells in response to Pc 4-PDT in vitro as well as in vivo 
(Oleinick et al., 2002; Miller et al., 2007). Evidence for apoptosis was 
also obtained in peripheral blood mononuclear cells from patients 
with Sezary Syndrome, a form of CTCL; at all PDT doses, there was 
significantly greater induction of apoptosis among CD4+ CD7− 
malignant T-cells compared to either non-malignant or monocytic 
cells (Lam et al., 2010). Finally, activated T-cells were found to be Frontiers in Oncology | Radiation Oncology    June 2011  | Volume 1  |  Article 14  |  6
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histopathologic, and biochemical 
evidence. Photochem. Photobiol. 58, 
771–776.
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